Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2025-12-26 @ 12:56 AM
NCT ID:
NCT03311334
Group ID:
EG000
Title:
Phase 1b - Arm 1
Description:
DSP-7888 Dosing Emulsion in combination with Nivolumab
DSP-7888 Dosing Emulsion: DSP-7888 Dosing Emulsion will be administered intradermally (ID) every 7 days until cycle 3, and then every 14 days for combination with Nivolumab arm or every 21 days for combination with Pembrolizumab arm.
Nivolumab: Nivolumab will be administered in the approved dose and schedule starting on Day 29 of the study.
Deaths Number Affected:
1
Deaths Number At Risk:
None
Serious Number Affected:
3
Serious Number At Risk:
7
Other Number Affected:
7
Other Number At Risk:
7
Study:
NCT03311334
Results Section:
NCT03311334
Adverse Events Module:
NCT03311334